目的
報告加強內視鏡睫狀體光凝固術（E C Pplus） 及內視鏡全視網膜光凝固術（Endoscopic PRP）用於增殖性糖尿病視網膜病變（PDR）併 發新生血管性青光眼（NVG）的治療結果。
方法
本研究為回溯性研究，蒐集一家醫學中心2014 年11月至2016年11月期間PDR合併NVG的患者。所 有納入對象均接受ECP-plus及endoscopic PRP，並 且在術後1天、1週、2週、1個月，3個月和6個月進 行檢查，並記錄及統計其成功率。
結果
在研究24個月期間共納入13個患者的14隻眼 睛。手術後所有患者的眼壓值均低於手術前數 值。術前平均眼壓33.9±6.0mmHg，治療後第1天 11.7±3.2mmHg，第1個月19.7±3.8mmHg，第6個 月19.8±3.0mmHg。所有納入的患者都無發生術中 及術後嚴重併發症。
結論
在本篇研究中治療後眼壓降低幅度從43％（6 個月）到66％（1天）不等。結果顯示ECP-plus及 endoscopic PRP用於增殖性糖尿病視網膜病變是有效 且安全的方式。

Purposes We reported the treatment outcomes for patients with peripheral diabetic retinopathy (PDR) complicated by neovascular glaucoma (NVG) who underwent pars plana endoscopic cyclophotocoagulation of the ciliary processes (ECP-plus) and endoscopyassisted panretinal photocoagulation (Endoscopic PRP). Methods This is a retrospective study. Clinical data of patients with PDR complicated by NVG who visited Taichung Veterans General Hospital between November 1, 2014 to November 1, 2016 were collected. All included subjects underwent ECP-plus and endoscopic PRP. Post-procedural data were collected at Day 1, Week 1, Week 2, Month 1, Month 3, and Month 6 after surgery, and successful treatment rates were recorded. Results During the 24-month study period, a total of 13 patients (14 eyes) were included. After the procedures, all patients had lower intraocular pressure (IOP) values compared with the preoperative value. The mean pre-procedural IOP was 33.9±6.0 mmHg and the post-procedural IOPs were 11.7±3.2 mmHg (Day 1), 19.7±3.8 mmHg (Month 1), and 19.8±3.0 mmHg (Month 6). None of the patients suffered from severe complications during and after the treatment. Conclusions The post-treatment reduction in IOP ranged from 43% (Month 6) to 66% (Day 1). The results showed that ECP-plus and endoscopic PRP is an effective and safe treatment for patients with PDR complicated by NVG.